AU6586298A - Glucagon-like peptide-1 analogs - Google Patents

Glucagon-like peptide-1 analogs

Info

Publication number
AU6586298A
AU6586298A AU65862/98A AU6586298A AU6586298A AU 6586298 A AU6586298 A AU 6586298A AU 65862/98 A AU65862/98 A AU 65862/98A AU 6586298 A AU6586298 A AU 6586298A AU 6586298 A AU6586298 A AU 6586298A
Authority
AU
Australia
Prior art keywords
glucagon
analogs
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65862/98A
Inventor
James A Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU6586298A publication Critical patent/AU6586298A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU65862/98A 1997-03-31 1998-03-25 Glucagon-like peptide-1 analogs Abandoned AU6586298A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4116797P 1997-03-31 1997-03-31
US60041167 1997-03-31
PCT/US1998/005945 WO1998043658A1 (en) 1997-03-31 1998-03-25 Glucagon-like peptide-1 analogs

Publications (1)

Publication Number Publication Date
AU6586298A true AU6586298A (en) 1998-10-22

Family

ID=21915105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65862/98A Abandoned AU6586298A (en) 1997-03-31 1998-03-25 Glucagon-like peptide-1 analogs

Country Status (2)

Country Link
AU (1) AU6586298A (en)
WO (1) WO1998043658A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777283B1 (en) * 1998-04-10 2000-11-24 Adir NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
ES2302390T3 (en) * 1998-12-07 2008-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. GLP-1 ANALOGS
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EA003922B1 (en) 1999-05-17 2003-10-30 Конджачем, Инк. Long lasting insulinotropic peptides
ATE309818T1 (en) 2000-03-08 2005-12-15 Novo Nordisk As LOWERING SERUM CHOLESTEROL
US6706689B2 (en) * 2000-05-19 2004-03-16 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with GLP-1
ATE416784T1 (en) 2000-12-01 2008-12-15 Takeda Pharmaceutical METHOD FOR PRODUCING A PREPARATION WITH A BIOACTIVE SUBSTANCE
HUE038395T2 (en) 2003-11-20 2018-10-29 Novo Nordisk As Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
DE602004031455D1 (en) 2003-12-09 2011-03-31 Novo Nordisk As REGULATION OF FOOD PREFERENCE WITH GLP-1 AGONISTS
BRPI0506694A (en) 2004-01-08 2007-05-02 Theratechnologies Inc Long-acting glucagon-like peptide-1 analogs
CN1950078A (en) 2004-06-11 2007-04-18 诺和诺德公司 Counteracting drug-induced obesity using glp-1 agonists
US8097586B2 (en) 2005-01-14 2012-01-17 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exedins and uses thereof
JP4945555B2 (en) 2005-05-10 2012-06-06 ラボラトワール フルニエ エス・アー Novel use of liver X receptor agonist
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
WO2008019147A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
JP6224586B2 (en) 2012-07-10 2017-11-01 武田薬品工業株式会社 Injectable preparation
CA3082033A1 (en) 2017-08-24 2019-02-28 Novo Nordisk A\S Glp-1 compositions and uses thereof
PE20230819A1 (en) 2020-02-18 2023-05-19 Novo Nordisk As COMPOSITIONS AND USES OF GLP-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0879279A4 (en) * 1996-02-06 2000-07-12 Lilly Co Eli Diabetes therapy

Also Published As

Publication number Publication date
WO1998043658A1 (en) 1998-10-08

Similar Documents

Publication Publication Date Title
IL136377A0 (en) Glucagon-like peptide-1 crystals
AU6586298A (en) Glucagon-like peptide-1 analogs
AU1617399A (en) Glp-1 formulations
HUP9903714A3 (en) Glp-1 derivatives
AU2610599A (en) N-terminally truncated glp-1 derivatives
ZA981343B (en) Sulfonylurea-glitazone combinations for diabetes
AU2524995A (en) Neurokinine (tachykinine) antagonists
AU9501798A (en) Low work-function electrode
AU9036098A (en) Parallel mechanism
AU1274099A (en) Low work-function electrode
AU9552498A (en) Phthalocyanine analogs
AU8747498A (en) Food-preservative composition
AU9066598A (en) Substituted 4-benzoyl-pyrazoles
AU8917398A (en) Torch
AU5203698A (en) Fluid-treatment assemblies
EP0903415A3 (en) Structure expansée
AU8121998A (en) Composition
AU2394697A (en) Porcine retrovirus
AU5953598A (en) Plaque-inhibiting composites
ZA984895B (en) Solvent replacement
AU8072498A (en) Heregulin-like factor
AU1098499A (en) Emulsifier-lipid composition
AU6090898A (en) Substituted 4-benzoyl-pyrazoles
ZA977791B (en) GLP-1 derivatives.
ZA200304047B (en) Analogues of GLP-1.